Please assess the completion status of the following clinical trial:

Trial Title: Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent;~* Patients over the age of 18;~* Recently confirmed mucinous cystic pancreatic neoplasm; may be confirmed by presence of mucin, cyst fluid carcinoembryonic antigen (CEA) above 192 U/L, or other reliable diagnostic means such as endomicroscopy; KRAS analysis may also be performed at the discretion of the Investigator;~* Unilocular cyst with diameter of at least 1.5 cm but no more than 4 cm;~* Normal hematologic, hepatic, and renal function at study entry;~* Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.\*~  * Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, is at least one year postmenopausal or has undergone tubal ligation. For the purposes of this study, adequate birth control includes at least one medically approved and highly effective method of birth control, defined as those which result in a low failure rate (i.e., \< 1% per year) when used consistently and correctly, such as implants, injectables and oral contraceptives combined with the use of condoms. Only male patients whose vasectomy has been confirmed by semen analysis at least 3 months after the vasectomy are allowed not to use acceptable contraceptive methods.~Exclusion Criteria:~* Positive cytology indicating malignancy;~* Thrombotic or embolic events;~* Known hypersensitivity to study agent;~* Known drug or alcohol abuse;~* Pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: NanoPac® 6 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Dose Escalation: NanoPac® 10 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Dose Escalation: NanoPac® 15 mg/mL (Type: EXPERIMENTAL): Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
- Second Phase: NanoPac® at Best Dose (Type: EXPERIMENTAL): Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).